INNOVIVA, INC. Unrealized Gain (Loss) on Investments
INNOVIVA, INC. (INVA) reported Unrealized Gain (Loss) on Investments of -$66.45 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2022-11-09
- INNOVIVA, INC. unrealized gain (loss) on investments for the quarter ending 2022-09-30 was $1.56M, a 95.33% decline year-over-year.
- INNOVIVA, INC. unrealized gain (loss) on investments for the quarter ending 2022-06-30 was -$58.60M, a 232.06% decline year-over-year.
- INNOVIVA, INC. unrealized gain (loss) on investments for the quarter ending 2022-03-31 was -$9.41M, a 117.21% decline year-over-year.
- INNOVIVA, INC. unrealized gain (loss) on investments for the quarter ending 2021-12-31 was -$43.18M, a 491.37% decline year-over-year.
- INNOVIVA, INC. unrealized gain (loss) on investments for fiscal 2021 was $89.31M, a 77.63% increase from fiscal 2020.
- INNOVIVA, INC. unrealized gain (loss) on investments for fiscal 2020 was $50.28M.
- INNOVIVA, INC. unrealized gain (loss) on investments for fiscal 2019 was $0.00.
- INNOVIVA, INC. unrealized gain (loss) on investments for fiscal 2018 was $0.00.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$57.04M derived: sum of 2 quarters · filed 2022-11-09 | -$66.45M 10-Q · filed 2022-11-09 | -$109.62M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | -$58.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$68.01M 10-Q · filed 2022-07-27 | -$111.19M derived: sum of 3 quarters · filed 2022-07-27 | -$77.75M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | -$9.41M 10-Q · filed 2022-05-05 | -$52.59M derived: sum of 2 quarters · filed 2022-05-05 | -$19.15M derived: sum of 3 quarters · filed 2022-11-09 | $25.23M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$43.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | -$9.74M derived: sum of 2 quarters · filed 2022-11-09 | $34.64M derived: sum of 3 quarters · filed 2022-11-09 | $89.31M 10-K/A · filed 2022-03-17 |
| 2021-09-30 | $33.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $77.81M derived: sum of 2 quarters · filed 2022-11-09 | $132.49M 10-Q · filed 2022-11-09 | $143.52M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $44.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $99.05M 10-Q · filed 2022-07-27 | $110.08M derived: sum of 3 quarters · filed 2022-07-27 | $80.71M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $54.67M 10-Q · filed 2022-05-05 | $65.70M derived: sum of 2 quarters · filed 2022-05-05 | $36.34M derived: sum of 3 quarters · filed 2022-05-05 | $83.03M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $11.03M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | -$18.34M derived: sum of 2 quarters · filed 2022-03-17 | $28.36M derived: sum of 3 quarters · filed 2022-03-17 | $50.28M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | -$29.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $17.33M derived: sum of 2 quarters · filed 2021-10-27 | $39.24M 10-Q · filed 2021-10-27 | $39.24M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $46.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $68.61M 10-Q · filed 2021-07-29 | $68.61M derived: sum of 3 quarters · filed 2022-03-17 | $68.61M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $21.91M 10-Q · filed 2021-04-28 | $21.91M derived: sum of 2 quarters · filed 2022-03-17 | $21.91M derived: sum of 3 quarters · filed 2022-03-17 | $21.91M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $0.00 derived: sum of 2 quarters · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $0.00 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |